ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 1548
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

More from this programme

About the episode

We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).

APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1 to receive either intravenous patisiran or a placebo. 

Interview Questions:
1. What is the importance of this study? 
2. What is the mechanism of action of the study drug (patisiran)? 
4. What was study design, outcome measures and patient population?
5. What are the findings to date? What conclusions can be made?
6. Are there any specific patient subgroups with cardiomyopathy for whom patisiran may be more or less effective?
7. What are the next steps?

Faculty Biographies

Marianna Fontana

View full profile


You must be to comment. If you are not registered, you can register here.